[Skip to Content]
[Skip to Content Landing]
December 1984

Methotrexate and Etretinate in the Treatment of Psoriasis

Author Affiliations

Clinical Pharmacology Unit Department of Dermatology University of Michigan Medical Center Ann Arbor, MI 48109-0010

Arch Dermatol. 1984;120(12):1555-1556. doi:10.1001/archderm.1984.01650480017004

To the Editor.—  In the February Archives, Zachariae1 presented a case report of severe, life-threatening hepatitis in a patient when concurrent therapy with methotrexate and etretinate was undertaken. Dr Zachariae's letter recounted a case previously reported in Dermatologica by two of his associates.2One key issue that was not clear in Zachariae's letter concerns the exact length of time the patient was actually receiving combination therapy. In the Dermatologica article, the patient apparently received therapy with both methotrexate and etretinate for about four months (November 1980 to March 1981). However, in the report by Zachariae involving the same 47-year-old woman, the

First Page Preview View Large
First page PDF preview
First page PDF preview